-
Cyclosporin A as a Mitophagy Assay Tool
2026-09-15
Cyclosporin A is more than an immunosuppressant: it can help interrogate mitochondrial quality control in inflammatory cartilage models. This article explains how to interpret cyclosporine experiments, reproduce the ajugol study logic, and avoid treating mitophagy inhibition as pathway proof.
-
MK-5108 (VX-689) Aurora A Assay Workflow
2026-09-15
MK-5108, also called VX-689, enables selective Aurora A interrogation across biochemical, cell-cycle, proliferation, and xenograft workflows. This practical guide connects the compound’s strong Aurora A potency with retinoblastoma findings, assay design, dose selection, and troubleshooting.
-
Species-Specific Shh Control of Penile Development
2026-09-14
The 2025 Cells study shows that guinea pig and mouse penile development diverge through differences in Shh, Fgf10, and Fgfr2 expression, helping explain why guinea pigs form an open urethral groove whereas mice do not. By combining comparative expression profiling with ex vivo perturbation, the work provides a stronger mechanistic framework for interpreting species-specific urethral and preputial morphogenesis.
-
SCH772984 ERK1/2 Inhibitor Workflow
2026-09-14
Build reproducible MAPK/ERK pathway inhibition experiments with SCH772984, from phospho-signaling validation to mutation-aware proliferation and xenograft studies. The workflow also shows how to test, without overclaiming, whether ERK signaling contributes to the angiotensin II–HIF-1α–HILPDA radioresistance axis described in nasopharyngeal carcinoma.
-
Palonosetron hydrochloride Assay Workflow Guide
2026-09-13
Build reproducible 5-HT3 receptor assays around subtype-resolved functional, binding, and kinetic measurements. This guide also shows how the same compound can support OCT2 and MATE1 transporter inhibition studies and translational cancer research without conflating assay domains.
-
JNK-IN-7: Selective JNK Inhibitor for Apoptosis
2026-09-12
JNK-IN-7 is a selective JNK inhibitor that targets JNK1, JNK2, and JNK3 and suppresses c-Jun phosphorylation through covalent kinase engagement. Its defined isoform potency and activity in innate immune models support MAPK signaling pathway research, while its higher-concentration Pellino 1 activity requires careful assay interpretation.
-
From Fluorescence to Function in mRNA Delivery
2026-09-12
A mechanistic and strategic guide to using ARCA Cy5 EGFP mRNA (5-moUTP) to distinguish cellular uptake from productive translation, strengthen lipid nanoparticle workflows, and improve translational decision-making.
-
ML385: Turning NRF2 Biology into Translational Decisions
2026-09-11
ML385 provides a practical way to test whether NRF2-dependent antioxidant signaling is causal in cancer therapeutic resistance, oxidative stress, and ferroptosis-related phenotypes. This thought-leadership guide connects NSCLC evidence with emerging neuro-metabolic research while defining rigorous experimental boundaries.
-
GLP-1R Crosstalk Revealed by FRET cAMP Assays
2026-09-11
Chepurny and colleagues used high-throughput FRET assays for cAMP, pharmacological probes, cellular validation, and molecular modeling to show that glucagon can activate the GLP-1 receptor in addition to its canonical glucagon receptor. The findings expose receptor promiscuity relevant to GLP-1 receptor signaling research and provide a framework for interpreting dual- and triagonist activity in metabolic regulation studies.
-
Dovitinib (TKI-258) Experimental Workflows
2026-09-10
Dovitinib (TKI-258) enables mechanism-focused studies of FLT3, c-Kit, FGFR, VEGFR, and PDGFR signaling rather than simple end-point cytotoxicity testing. This workflow pairs RTK inhibition with phospho-protein profiling and apoptosis assays, while using interferon-gamma biology to prevent misleading conclusions about ERK-dependent melanoma cell death.
-
Radicicol as a Mechanistic Probe for Translational Biology
2026-09-10
Radicicol is more than a conventional Hsp90 inhibitor: it is a stress-network probe that can connect chaperone biology, adipocyte differentiation, apoptosis, kinase regulation, and inflammation. This article presents a translational framework for using Radicicol with appropriate controls, evidence boundaries, and cross-domain decision points.
-
RNA Pol II Loss Activates Apoptosis Beyond Transcription
2026-09-09
Harper and colleagues show that RNA polymerase II inhibition can trigger apoptosis through active signaling caused by depletion of hypophosphorylated RNA Pol IIA, rather than through transcriptional collapse alone. Their functional-genomic framework identifies a Pol II degradation-dependent apoptotic response that may explain the lethality of several mechanistically diverse anticancer compounds.
-
CARMIL Membrane Binding and Actin Assembly
2026-09-09
This preprint identifies the CARMIL membrane-binding domain as more than a targeting module: it can recruit capping protein to lipid surfaces, promote actin assembly, and disengage after capping protein binding. The findings provide a biochemical model for how membrane-localized CARMIL coordinates capping protein activation with subsequent activity near the membrane.
-
LY2886721: A Practical BACE Inhibitor Workflow
2026-09-08
LY2886721 enables controlled BACE1 inhibition across amyloid-production, APP-processing, and neuronal synaptic-function assays. This workflow-focused guide combines benchmark potency data with practical dosing, handling, assay-design, and troubleshooting strategies for reproducible Alzheimer’s disease research.
-
Temozolomide in ATRX-Deficient Glioma Assays
2026-09-08
Temozolomide is a small-molecule alkylating agent whose value extends beyond generic cytotoxicity assays. This guide explains how ATRX status, DNA repair capacity, formulation controls, and combination design can improve glioma research and chemotherapy resistance studies.